JT-SAFE-V2: Safety-by-Design Foundation Model with World-Context Data

By: Junlan Feng · Fanyu Meng · Chong Long · Pengyu Cong · Duqing Wang · Yan Zheng · Yuyao Zhang · Xuanchang Gao · Ye Yuan · Yunfei Ma · Zhijie Ren · Fan Yang · Na Wu · Di Jin · Chao Deng

26 May 2026 at 12:00

arXiv:2605.24414v1 Announce Type: new Abstract: We introduce JT-Safe-V2, a large language model designed to advance the safety and trustworthiness of foundation models, extending our previous JT-Safe model toward a more comprehensive safety-by-design paradigm. JT-Safe-V2 emphasizes the joint optimization of general intelligence and safety-by-design through several key innovations: enriching pre-training data with contextual world knowledge, high-certainty pre-training procedures, and safety strengthening post-training mechanisms for enterprise-oriented agentic capabilities. Building on these safety-enhanced foundation models, we propose Safe-MoMA (Safe Mixture of Models and Agents), a framework that enables traceable and efficient inference through the orchestrated deployment of multiple models and agents. Extensive evaluations demonstrate that JT-Safe-V2 achieves state-of-the-art performance across both general intelligence and safety benchmarks. Moreover, Safe-MoMA reduces inference costs by more than 30\% compared to using the largest standalone model baseline while maintaining comparable performance. To facilitate future research on safety-by-design foundation models, we publicly release the post-trained JT-Safe-V2-35B model checkpoint.

Ubiquitin-specific protease 11 suppresses cuproptosis in colorectal cancer by regulating the ubiquitination and stability of ISCU

Oncogenesis - nature.com science feeds

By: Hailin Ke · Guowei Zhang · Weili Lin · Yuecui Jiang · Meina Wu · Yueyi Zhang · Weiyang Song · Fuhai Wang · Songling Yan

8 May 2026 at 08:00

Oncogenesis, Published online: 08 May 2026; doi:10.1038/s41389-026-00621-5

Ubiquitin-specific protease 11 suppresses cuproptosis in colorectal cancer by regulating the ubiquitination and stability of ISCU

Multi-omics integration and Mendelian randomization reveal the mechanisms and experimental validation of curcumin targeting the RXRA-PI3K/AKT axis to enhance cisplatin sensitivity in gastric cancer

Omics in Gastric

By: Xiaoran Sun · Na Wu · Xue Bai · Xiang Zhang · Rui Wang · Shuai Du · Li Liu · Duo Li

1 May 2026 at 18:00

Front Oncol. 2026 Apr 15;16:1791971. doi: 10.3389/fonc.2026.1791971. eCollection 2026.

ABSTRACT

OBJECTIVE: This study aimed to integrate multi-omics analyses with genetic causal inference to identify key genes associated with cisplatin resistance in gastric cancer and to evaluate the potential mechanism by which curcumin enhances cisplatin sensitivity through relevant pathways.

METHODS: Cisplatin resistance-related transcriptomic datasets(GSE14210 and GSE31811) and a gastric cancer single-cell transcriptomic dataset (GSE183904) were obtained from the Gene Expression Omnibus(GEO)database. Differential expression analysis was performed to identify resistance-associated differentially expressed genes(DEGs),followed by GO and KEGG enrichment analyses. Putative curcumin targets were collected and intersected with DEGs to obtain candidate genes. Mendelian randomization (MR) analysis was conducted using the TwoSampleMR framework to evaluate the genetic association between RXRA expression and gastric cancer risk, with robustness and sensitivity analyses based on multiple MR methods. RXRA expression was further evaluated, along with pathway activity assessment using GSEA and GSVA, and molecular docking was performed to explore the potential binding of curcumin to RXRA. In vitro experiments were performed using the cisplatin-resistant gastric cancer cell lineNCI-N87/DDP. Drug effects and chemosensitization under combination treatment were assessed by CCK-8 assays, synergy was evaluated using the combination index(CI),and changes in key proteins in thePI3K/AKT pathway were measured by Western blotting.

RESULTS: A total of 595 DEGs associated with cisplatin resistance were identified. Functional enrichment analyses indicated that these DEGs were mainly involved in extracellular matrix remodeling and adhesion, secretion and vesicular transport, and signaling pathways including PI3K-Akt.The intersection of curcumin targets with DEGs highlighted RXRA as a key candidate gene. MR results indicated that genetically predicted increased RXRA expression was significantly associated with elevated gastric cancer risk (OR = 4.216,95%CI:1.201-14.797,P=0.025). GSEA and GSVA suggested that high RXRA expression was associated with altered activity of pathways related to lysosome, proteasome, oxidative phosphorylation, and the pentose phosphate pathway. Single-cell analysis indicated that RXRA was mainly expressed in tissue stem cells and fibroblasts. Molecular docking predicted a feasible interaction between curcumin and RXRA. In vitro experiments demonstrated that curcumin inhibited the viability of resistant cells and showed a synergistic trend when combined with cisplatin. Western blotting revealed decreased p-PI3K and p-AKT levels following curcumin treatment, supporting an inhibitory effect on the PI3K/AKT pathway.

CONCLUSION: These findings highlight RXRA as a candidate gene associated with cisplatin resistance-related programs in gastric cancer. Curcumin may enhance cisplatin sensitivity by influencing RXRA-associated transcriptional networks and suppressing PI3K/AKT signaling. This study provides new candidate targets and experimental evidence for mechanistic investigation and combination treatment strategies to overcome cisplatin resistance in gastric cancer.

PMID:42063729 | PMC:PMC13124633 | DOI:10.3389/fonc.2026.1791971

Reading view